Armin Giese

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6337819/publications.pdf

Version: 2024-02-01

170	15,204	23567 58	19190 118
papers	citations	h-index	g-index

178	178	178	14924
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
2	Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Annals of Neurology, 1999, 46, 224-233.	5.3	1,314
3	The cellular prion protein binds copper in vivo. Nature, 1997, 390, 684-687.	27.8	1,170
4	Different Species of Î±-Synuclein Oligomers Induce Calcium Influx and Seeding. Journal of Neuroscience, 2007, 27, 9220-9232.	3.6	708
5	Inhibition of mitochondrial fusion by Î±-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO Journal, 2010, 29, 3571-3589.	7.8	431
6	Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinsonâ€™s disease. Acta Neuropathologica, 2013, 125, 795-813.	7.7	327
7	Evidence of Presynaptic Location and Function of the Prion Protein. Journal of Neuroscience, 1999, 19, 8866-8875.	3.6	298
8	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	12.4	289
9	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Movement Disorders, 2014, 29, 1758-1766.	3.9	286
10	Typing prion isoforms. Nature, 1997, 386, 232-233.	27.8	268
11	Chaperonin TRiC Promotes the Assembly of polyQ Expansion Proteins into Nontoxic Oligomers. Molecular Cell, 2006, 23, 887-897.	9.7	259
12	Inhibition and disaggregation of Î±-synuclein oligomers by natural polyphenolic compounds. FEBS Letters, 2011, 585, 1113-1120.	2.8	240
13	Incidence and spectrum of sporadic Creutzfeldtâ€“Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathologica, 2009, 118, 659-671.	7.7	224
14	Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5468-5473.	7.1	220
15	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
16	Role of Microglia in Neuronal Cell Death in Prion Disease. Brain Pathology, 1998, 8, 449-457.	4.1	209
17	Single Particle Characterization of Iron-induced Pore-forming Î±-Synuclein Oligomers. Journal of Biological Chemistry, 2008, 283, 10992-11003.	3.4	204
18	The Paraffin-Embedded Tissue Blot Detects PrPSc Early in the Incubation Time in Prion Diseases. American Journal of Pathology, 2000, 156, 51-56.	3.8	192

#	Article	IF	Citations
19	Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet, The, 1998, 351, 1081-1085.	13.7	191
20	Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathologica, 2012, 124, 517-529.	7.7	184
21	DNA methylation analysis on purified neurons and glia dissects age and Alzheimerâ€™s disease-specific changes in the human cortex. Epigenetics and Chromatin, 2018, 11, 41.	3.9	173
22	Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Annals of Clinical and Translational Neurology, 2015, 2, 295-301.	3.7	160
23	Current clinical diagnosis in Creutzfeldt-Jakob disease: Identification of uncommon variants. Annals of Neurology, 2000, 48, 323-329.	5.3	159
24	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica, 2015, 130, 537-555.	7.7	157
25	Neuronal Cell Death in Scrapie-Infected Mice Is Due to Apoptosis. Brain Pathology, 1995, 5, 213-221.	4.1	149
26	Extracellular vesicle sorting of Î±-Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
27	The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärzteblatt International, 2016, 113, 61-9.	0.9	135
28	Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathologica, 2011, 121, 91-112.	7.7	134
29	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
30	Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 2532-2543.	2.6	120
31	Effects of Different Experimental Conditions on the PrPSc Core Generated by Protease Digestion. Journal of Biological Chemistry, 2004, 279, 16797-16804.	3.4	118
32	Ageâ€Dependent Levels of 5â€Methylâ€, 5â€Hydroxymethylâ€, and 5â€Formylcytosine in Human and Mouse Brain Tissues. Angewandte Chemie - International Edition, 2015, 54, 12511-12514.	13.8	116
33	Autocatalytic self-propagation of misfolded prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12207-12211.	7.1	109
34	The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathologica, 2014, 127, 779-780.	7.7	103
35	Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7756-7761.	7.1	98
36	Identification of Anti-prion Compounds as Efficient Inhibitors of Polyglutamine Protein Aggregation in a Zebrafish Model. Journal of Biological Chemistry, 2007, 282, 9195-9203.	3.4	95

#	Article	IF	Citations
37	Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. BMJ: British Medical Journal, 1998, 316, 577-582.	2.3	94
38	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
39	Effect of metal ions on de novo aggregation of full-length prion protein. Biochemical and Biophysical Research Communications, 2004, 320, 1240-1246.	2.1	92
40	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
41	Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Human Molecular Genetics, 2011, 20, 3256-3265.	2.9	87
42	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	3.3	81
43	Increased Î±-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Experimental Neurology, 2009, 215, 201-208.	4.1	80
44	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.2	79
45	Depopulation of dense Î±-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinsonâ€™s disease model. Acta Neuropathologica, 2019, 138, 575-595.	7.7	79
46	Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. British Journal of Haematology, 2000, 108, 488-495.	2.5	75
47	Characterization of Truncated Forms of Abnormal Prion Protein in Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2008, 283, 30557-30565.	3.4	75
48	Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by Î±-Synuclein Oligomers in Lipid Membranes. PLoS ONE, 2012, 7, e42545.	2.5	75
49	Interaction of Î±-synuclein with biomembranes in Parkinson's disease â€”role of cardiolipin. Progress in Lipid Research, 2016, 61, 73-82.	11.6	73
50	CADASIL mutations enhance spontaneous multimerization of NOTCH3. Human Molecular Genetics, 2009, 18, 2761-2767.	2.9	72
51	Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Parkinsonism and Related Disorders, 2016, 33, 115-121.	2.2	72
52	Anle138b modulates Î±â€synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders, 2019, 34, 255-263.	3.9	72
53	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology, 2018, 20, 279-288.	1.2	71
54	Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain, 2010, 133, 3030-3042.	7.6	69

#	Article	IF	Citations
55	Dynamic ¹⁸<scp>Fâ€FET PET</scp> in suspected <scp>WHO</scp> grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 2015, 136, 2132-2145.	5.1	68
56	Molecular Dynamics Simulations Indicate a Possible Role of Parallel Î²-Helices in Seeded Aggregation of Poly-Gln. Biophysical Journal, 2005, 88, 2442-2451.	0.5	66
57	Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets. Journal of Virology, 2005, 79, 7785-7791.	3.4	64
58	The diphenylpyrazole compound anle138b blocks AÎ² channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	6.9	63
59	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
60	Next-Generation Sequencing Reveals Regional Differences of the Î±-Synuclein Methylation State Independent of Lewy Body Disease. NeuroMolecular Medicine, 2011, 13, 310-320.	3.4	61
61	A refined method for molecular typing reveals that co-occurrence of PrPSc types in Creutzfeldtâ€“Jakob disease is not the rule. Laboratory Investigation, 2007, 87, 1103-1112.	3.7	60
62	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced Î±-synuclein oligomers. Journal of Neurochemistry, 2011, 117, 868-878.	3.9	60
63	Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with Î±-synuclein at the single molecule level. Molecular Neurodegeneration, 2012, 7, 35.	10.8	60
64	Generation and deposition of AÎ²43 by the virtually inactive presenilinâ€1 L435F mutant contradicts the presenilin lossâ€ofâ€function hypothesis of Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 458-465.	6.9	60
65	Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes. ACS Chemical Neuroscience, 2019, 10, 3815-3829.	3.5	60
66	Generation of Ferric Iron Links Oxidative Stress to Î±-Synuclein Oligomer Formation. Journal of Parkinson's Disease, 2011, 1, 205-216.	2.8	58
67	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica, 2015, 130, 619-631.	7.7	58
68	Seeding and transgenic overexpression of alphaâ€synuclein triggers dendritic spine pathology in the neocortex. EMBO Molecular Medicine, 2017, 9, 716-731.	6.9	58
69	Sequestration of latent TGF-Î² binding protein 1 into CADASIL-related Notch3-ECD deposits. Acta Neuropathologica Communications, 2014, 2, 96.	5.2	54
70	Converse modulation of toxic Î±-synuclein oligomers in living cells by Nâ€²-benzylidene-benzohydrazide derivates and ferric iron. Biochemical and Biophysical Research Communications, 2010, 391, 461-466.	2.1	52
71	Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to Î±-synuclein aggregates. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1884-1890.	2.4	52
72	Generation of genuine prion infectivity by serial PMCA. Veterinary Microbiology, 2007, 123, 346-357.	1.9	51

#	Article	IF	Citations
73	Single particle analysis of tau oligomer formation induced by metal ions and organic solvents. Biochemical and Biophysical Research Communications, 2011, 411, 190-196.	2.1	51
74	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochirurgica, 2014, 156, 1427-1440.	1.7	51
75	TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. Journal of Neuro-Oncology, 2018, 139, 671-678.	2.9	51
76	Cell-free formation of misfolded prion protein with authentic prion infectivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15818-15823.	7.1	50
77	Polyphenolic compounds are novel protective agents against lipid membrane damage by Î±-synuclein aggregates in vitro. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2502-2510.	2.6	50
78	[11C]MODAG-001â€"towards a PET tracer targeting Î±-synuclein aggregates. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1759-1772.	6.4	50
79	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	3.9	48
80	Single particle detection and characterization of synuclein co-aggregation. Biochemical and Biophysical Research Communications, 2005, 333, 1202-1210.	2.1	47
81	Identification of Polyphenolic Compounds and Black Tea Extract as Potent Inhibitors of Lipid Membrane Destabilization by AÎ²42 Aggregates. Journal of Alzheimer's Disease, 2011, 27, 767-779.	2.6	46
82	Cysteine-Sparing CADASIL Mutations in NOTCH3 Show Proaggregatory Properties In Vitro. Stroke, 2015, 46, 786-792.	2.0	46
83	Single particle analysis of manganese-induced prion protein aggregates. Biochemical and Biophysical Research Communications, 2005, 329, 1200-1207.	2.1	45
84	Different Effects of Î±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements. ACS Chemical Neuroscience, 2019, 10, 1649-1659.	3.5	44
85	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Experimental Neurology, 2012, 237, 470-476.	4.1	41
86	Elevated Levels of Methylmalonate and Homocysteine in Parkinsonâ€™s Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. Dementia and Geriatric Cognitive Disorders, 2010, 29, 553-559.	1.5	40
87	Two Different Binding Modes of Î±-Synuclein to Lipid Vesicles Depending on its Aggregation State. Biophysical Journal, 2012, 102, 1646-1655.	0.5	39
88	Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183064.	2.6	38
89	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
90	Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. Acta Neuropathologica Communications, 2013, 1, 44.	5.2	36

#	Article	IF	Citations
91	MR imaging differentiation of Fe2+ and Fe3+ based on relaxation and magnetic susceptibility properties. Neuroradiology, 2017, 59, 403-409.	2.2	36
92	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Journal of Neuropathology and Experimental Neurology, 2016, 75, 408-414.	1.7	35
93	¹¹C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to Î±â€Synuclein Fibrils inâ€...vitro and Crosses the Bloodâ€Brain Barrier. ChemMedChem, 2020, 15, 411-415.	3.2	35
94	Analyses of Protease Resistance and Aggregation State of Abnormal Prion Protein across the Spectrum of Human Prions. Journal of Biological Chemistry, 2013, 288, 27972-27985.	3.4	34
95	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
96	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
97	Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 424-427.	1.9	31
98	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. European Journal of Cancer, 2019, 107, 15-27.	2.8	30
99	Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein. Biochemical and Biophysical Research Communications, 2005, 326, 339-343.	2.1	29
100	Analysis of Conformational Stability of Abnormal Prion Protein Aggregates across the Spectrum of Creutzfeldt-Jakob Disease Prions. Journal of Virology, 2016, 90, 6244-6254.	3.4	29
101	Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Journal of Neuro-Oncology, 2016, 130, 591-599.	2.9	28
102	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimerâ€™s disease tau. Alzheimer's Research and Therapy, 2019, 11, 67.	6.2	28
103	Mouse Brain Synaptosomes Accumulate Copper-67 Efficiently by Two Distinct Processes Independent of Cellular Prion Protein. Journal of Molecular Neuroscience, 2005, 27, 347-354.	2.3	27
104	Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis. Journal of Neuroinflammation, 2011, 8, 7.	7.2	26
105	Immunoprofiling of glial tumours of the neurohypophysis suggests a common pituicytic origin of neoplastic cells. Pituitary, 2017, 20, 211-217.	2.9	26
106	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine, 2022, 80, 104021.	6.1	26
107	Treatment with diphenylâ€“pyrazole compound anle138b/c reveals that Î±-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4971-E4977.	7.1	25
108	An Unusual Case of Ectopic ACTH Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 63-67.	1.2	24

#	Article	IF	Citations
109	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. PLoS ONE, 2014, 9, e98906.	2.5	24
110	Phenotypic diversity of genetic Creutzfeldtâ€“Jakob disease: a histo-molecular-based classification. Acta Neuropathologica, 2021, 142, 707-728.	7.7	24
111	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Frontiers in Neuroscience, 2016, 10, 99.	2.8	23
112	An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathologica Communications, 2016, 4, 120.	5.2	22
113	Targeting Î±-synuclein by PD03 AFFITOPEÂ® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Translational Neurodegeneration, 2020, 9, 38.	8.0	22
114	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	3.9	22
115	Genotypeâ€“Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	3.9	22
116	From Highâ€Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease. ChemMedChem, 2011, 6, 1928-1937.	3.2	21
117	Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathologica, 2021, 141, 323-325.	7.7	20
118	Î±-Internexin in the Diagnosis of Oligodendroglial Tumors and Association With 1p/19q Status. Journal of Neuropathology and Experimental Neurology, 2011, 70, 970-978.	1.7	19
119	Photo-induced crosslinking of prion protein oligomers and prions. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 67-77.	3.0	18
120	Development and Implementation of a High-Throughput Compound Screening Assay for Targeting Disrupted ER Calcium Homeostasis in Alzheimer's Disease. PLoS ONE, 2013, 8, e80645.	2.5	18
121	Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Acta Neuropathologica, 2014, 127, 553-564.	7.7	17
122	Regional pattern of microgliosis in sporadic Creutzfeldtâ€Jakob disease in relation to phenotypic variants and disease progression. Neuropathology and Applied Neurobiology, 2018, 44, 574-589.	3.2	17
123	The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers. Scientific Reports, 2019, 9, 19023.	3.3	16
124	Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimerâ€™s disease. Translational Psychiatry, 2014, 4, e489-e489.	4.8	15
125	Automated PrPres amplification using indirect sonication. Journal of Proteomics, 2005, 63, 213-221.	2.4	13
126	Divergent Molecular Effects of Desmin Mutations on Protein Assembly in Myofibrillar Myopathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 415-424.	1.7	13

#	Article	IF	Citations
127	Presence of Phosphodiesterase Type 5 in the Spinal Cord and its Involvement in Bladder Outflow Obstruction Related Bladder Overactivity. Journal of Urology, 2013, 190, 1430-1435.	0.4	13
128	Diphenylpyrazole-Derived Compounds Increase Survival Time of Mice after Prion Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 4774-4781.	3.2	12
129	Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats. Neurourology and Urodynamics, 2016, 35, 464-470.	1.5	12
130	Repeated Peripheral Administrations of CpG Oligodeoxynucleotides Lead to Sustained CNS Immune Activation. Immunopharmacology and Immunotoxicology, 2007, 29, 413-424.	2.4	11
131	Differential effects of prion particle size on infectivity in vivo and in vitro. Biochemical and Biophysical Research Communications, 2008, 369, 924-928.	2.1	11
132	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS ONE, 2020, 15, e0231495.	2.5	11
133	First symptom guides diagnosis and prognosis in neurodegenerative diseasesâ€”a retrospective study of autopsy proven cases. European Journal of Neurology, 2021, 28, 1801-1811.	3.3	11
134	The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Acta Neuropathologica Communications, 2021, 9, 35.	5.2	11
135	Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. PLoS ONE, 2017, 12, e0188989.	2.5	11
136	Blood Î²-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.0000000000200002.	1.1	11
137	Unaltered prion protein cleavage in plasminogen-deficient mice. NeuroReport, 2006, 17, 527-530.	1.2	10
138	Synthesis of benzamide derivatives and their evaluation as antiprion agents. Bioorganic and Medicinal Chemistry, 2012, 20, 5001-5011.	3.0	10
139	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. Clinical Neurology and Neurosurgery, 2014, 122, 113-115.	1.4	10
140	Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 924-933.	1.7	10
141	Photophysics of diphenyl-pyrazole compounds in solutions and Î±-synuclein aggregates. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 800-807.	2.4	10
142	Adjunctive N -Acetyl- <scp>l</scp> -Cysteine in Treatment of Murine Pneumococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4825-4830.	3.2	9
143	Piperazine derivatives inhibit PrP/PrPres propagation in vitro and in vivo. Biochemical and Biophysical Research Communications, 2014, 445, 23-29.	2.1	9
144	The association of aphasia and right-sided motor impairment in corticobasal syndrome. Journal of Neurology, 2015, 262, 2241-2246.	3.6	9

#	Article	IF	Citations
145	K27M midline gliomas display malignant progression by imaging and histology. Neuropathology and Applied Neurobiology, 2017, 43, 458-462.	3.2	9
146	Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety. Journal of Neurology, 2021, 268, 367-376.	3.6	9
147	Comprehensive Neuropathologic Analysis of Genetic Prion Disease Associated With the E196K Mutation inPRNPReveals Phenotypic Heterogeneity. Journal of Neuropathology and Experimental Neurology, 2011, 70, 192-200.	1.7	8
148	Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. Scientific Reports, 2019, 9, 9100.	3.3	8
149	Binding of Metal-Ion-Induced Tau Oligomers to Lipid Surfaces Is Enhanced by GSK-3Î²-Mediated Phosphorylation. ACS Chemical Neuroscience, 2020, 11, 880-887.	3.5	8
150	The German FFI Cases. Brain Pathology, 1998, 8, 559-561.	4.1	7
151	Cell Type and Species-specific Patterns in Neuronal and Non-neuronal Methylomes of Human and Chimpanzee Cortices. Cerebral Cortex, 2018, 28, 3724-3739.	2.9	7
152	Potential sources of interference with the highly sensitive detection and quantification of alphaâ€synuclein seeds by qRTâ€QuIC. FEBS Open Bio, 2020, 10, 883-893.	2.3	6
153	Seizure prevalence in neurodegenerative diseasesâ€”a study of autopsy proven cases. European Journal of Neurology, 2022, 29, 12-18.	3.3	6
154	Epilepsy surgery in the first months of life: a large type IIb focal cortical dysplasia causing neonatal drugâ€resistant epilepsy. Epileptic Disorders, 2019, 21, 122-127.	1.3	5
155	Decreased prion protein expression in human peripheral blood leucocytes from patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2001, 112, 658-662.	2.5	4
156	Intracellular formation of Î±-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochemical and Biophysical Research Communications, 2016, 477, 76-82.	2.1	4
157	A Multi-Scale and Multi-Technique Approach for the Characterization of the Effects of Spatially Fractionated X-ray Radiation Therapies in a Preclinical Model. Cancers, 2021, 13, 4953.	3.7	4
158	Prion Protein as Copper-Binding Protein at the Synapse. , 2001, 59, 17-30.		3
159	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clinical Neurology and Neurosurgery, 2020, 195, 105924.	1.4	3
160	Travel-associated neurological disease terminated in a postmortem diagnosed atypical HSV-1 encephalitis after high-dose steroid therapy â€“ a case report. BMC Infectious Diseases, 2020, 20, 150.	2.9	3
161	Neuronal Degeneration and Cell Death in Prion Disease. , 1998, , 253-268.		3
162	The Small Molecule anle138b Shows Interaction with Î±-Synuclein Oligomers in Phospholipid Membranes. Biophysical Journal, 2018, 114, 560a.	0.5	2

#	Article	IF	Citations
163	MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results. Medical Oncology, 2018, 35, 103.	2.5	2
164	Protein-Drug Interactions in the Membrane: The Small Molecule Anle138b and its Binding to Î±-Synuclein Oligomers. Biophysical Journal, 2019, 116, 352a.	0.5	2
165	Correlation of dynamic ¹⁸FET-PET with IDH 1 mutation for prediction of outcome in anaplastic astrocytoma WHOÂ° III independently from tumor vascularisation.. Journal of Clinical Oncology, 2015, 33, 2037-2037.	1.6	2
166	Scanning for Intensely Fluorescent Targets (SIFT) in the Study of Protein Aggregation at the Single-Particle Level. , 2014, , 167-176.		0
167	The Novel Inhibitor â€œAnle145Câ€•Efficiently Inhibits Fibril Formation of Islet Amyloid Polypeptide (IAPP) and uses Distinctly Different Modes of Action in the Absence and Presence of Membranes. Biophysical Journal, 2015, 108, 256a.	0.5	0
168	Effect of the Novel Amyloid Inhibitor â€œanle145câ€•on Aggregation of Islet Amyloid Polypeptide and how it is Modulated by Membranes. Biophysical Journal, 2016, 110, 420a.	0.5	0
169	PATH-04. INFLUENCE OF INDIVIDUAL CpG METHYLATION STATUS OF THE MGMT PROMOTOR ON OUTCOME IN ADULT PATIENTS WITH GLIOBLASTOMA MULTIFORME RECEIVING ALKYLATING AGENT TREATMENT. Neuro-Oncology, 2019, 21, vi143-vi143.	1.2	0
170	Contrast enhancement as a prognostic factor in IDH1/2 mutant glioma.. Journal of Clinical Oncology, 2018, 36, 2029-2029.	1.6	0